{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:59:03Z","timestamp":1781240343573,"version":"3.54.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>\n                    Lymphoma is one of the most common neoplastic diseases in dogs, and T-cell lymphoma in particular has frequently been reported to show limited sensitivity to conventional chemotherapy from the onset of treatment when compared with B-cell lymphoma. Owing to its high-grade and aggressive clinical behavior, there is a strong need to explore novel therapeutic approaches for canine T-cell lymphoma, including strategies targeting aberrant gene regulation. In this study, we focused on the\n                    <jats:italic>epigenetic enzyme enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2)<\/jats:italic>\n                    and investigated its functional role in canine T-cell lymphoma. The\n                    <jats:italic>EZH2<\/jats:italic>\n                    gene was ectopically introduced into canine T-cell lymphoma cell lines using a lentiviral vector system, and colony-forming ability, and apoptosis rate were evaluated.\n                    <jats:italic>EZH2<\/jats:italic>\n                    overexpression significantly enhanced colony-forming capacity, suppressed apoptosis, and increased the number of viable cells compared with control cells. These findings indicate that elevated\n                    <jats:italic>EZH2<\/jats:italic>\n                    expression confers a survival advantage to canine T-cell lymphoma cells. The present study provides novel evidence that overexpression of\n                    <jats:italic>EZH2<\/jats:italic>\n                    itself promotes tumor cell survival and aggressiveness. Our results suggest that\n                    <jats:italic>EZH2<\/jats:italic>\n                    may play a functional role in the maintenance and progression of at least a subset of canine T-cell lymphoma and may represent a potential driver of tumor malignancy. These findings contribute to a deeper understanding of lymphomagenesis and support the potential of\n                    <jats:italic>EZH2<\/jats:italic>\n                    as a therapeutic target in canine T-cell lymphoma.\n                  <\/jats:p>","DOI":"10.3389\/fvets.2026.1823343","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:42:05Z","timestamp":1781239325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancer of zeste 2 polycomb repressive complex 2 subunit overexpression suppresses apoptosis in canine T-cell lymphoma: an in vitro functional analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Honoka","family":"Kawamura","sequence":"first","affiliation":[{"name":"Department of Veterinary Pathology, Nippon Veterinary and Life Science University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Ishikawa-Shinohara","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathology, Nippon Veterinary and Life Science University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathology, Nippon Veterinary and Life Science University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kohno","sequence":"additional","affiliation":[{"name":"Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Gonzalez-Astudillo","sequence":"additional","affiliation":[{"name":"School of Veterinary Science, The University of Queensland","place":["Gatton, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Aikawa","sequence":"additional","affiliation":[{"name":"Department of Immune Medicine, National Cancer Center Research Institute","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issay","family":"Kitabayashi","sequence":"additional","affiliation":[{"name":"Oncology Innovation Center\/Center for Translational Research, Fujita Health University","place":["Toyoake, Aichi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University","place":["Yoshida, Yamaguchi Prefecture, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Division of Cancer Cell Biology, Cancer Research Institute, Institute for Frontier Science Initiative, Kanazawa University","place":["Kanazawa, Japan"]},{"name":"Environmental Stress Research Center (eSRC), Kanazawa University","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Michishita","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathology, Nippon Veterinary and Life Science University","place":["Tokyo, Japan"]},{"name":"Center for One Health, One Welfare, Nippon Veterinary and Life Science University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukino","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathology, Nippon Veterinary and Life Science University","place":["Tokyo, Japan"]},{"name":"Laboratory of Veterinary Pathology, Cooperative Department of Veterinary Medicine, Tokyo University of Agriculture and Technology","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hon.2017","article-title":"The dog as a possible animal model for human non-Hodgkin lymphoma: a review","volume":"31","author":"Marconato","year":"2013","journal-title":"Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"ref5","first-page":"148","article-title":"EZH2 expression in naturally occurring canine tumors","volume":"68","author":"Choi","year":"2018","journal-title":"Comp Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/leu.2013.288","article-title":"EZH2 in normal and malignant hematopoiesis","volume":"28","author":"Lund","year":"2014","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1292\/jvms.12-0448","article-title":"Establishment of five canine lymphoma cell lines and tumor formation in a xenotransplantation model","volume":"75","author":"Umeki","year":"2013","journal-title":"J Vet Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.bjc.6605468","article-title":"Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells","volume":"102","author":"Murohashi","year":"2010","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/cdd.2011.48","article-title":"Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage","volume":"18","author":"Wu","year":"2011","journal-title":"Cell Death Differ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.18632\/oncoscience.288","article-title":"EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis","volume":"3","author":"Smonskey","year":"2016","journal-title":"Oncoscience"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"85624","DOI":"10.18632\/oncotarget.12928","article-title":"Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2","volume":"7","author":"Christofides","year":"2016","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and role of EZH2 in cancer","volume":"46","author":"Yamaguchi","year":"2014","journal-title":"Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"591843","DOI":"10.3389\/fonc.2020.591843","article-title":"Epigenetic mechanisms in canine cancer","volume":"10","author":"Xavier","year":"2020","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/leu.2013.94","article-title":"Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity","volume":"27","author":"Zhao","year":"2013","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41375-023-02006-8","article-title":"Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in mantle cell lymphoma","volume":"37","author":"Sircar","year":"2023","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/vetsci9080393","article-title":"Simultaneous analysis of the p16 gene and protein in canine lymphoma cells and their correlation with pRb phosphorylation","volume":"9","author":"Maylina","year":"2022","journal-title":"Vet Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/bloodadvances.2020002773","article-title":"Treating lymphoma is now a bit EZ-er","volume":"5","author":"Morin","year":"2021","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.18632\/oncotarget.2758","article-title":"Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth","volume":"6","author":"Barsotti","year":"2015","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2005-09-3585","article-title":"The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion","volume":"107","author":"Kamminga","year":"2006","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1823343\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:42:23Z","timestamp":1781239343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1823343\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"alternative-id":["10.3389\/fvets.2026.1823343"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1823343","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1823343"}}